Concall Analysis

Management Guidance

-->Total revenue of this quarter was 918.9 crores as compared to 427.3 crores for the same period a surge of 115%.

-->Net profit for the quarte was 320.4 crores as compared to 75 crores last year.

-->Lenalidomide sales was the major contributor to revenue and profitability says the management..

-->On the expense side company occurred a one time cost associated with retirement schemes and higher than usual R & D expenditure.

-->Management expects revalmind to do well for next few quarters -->Management still looking out on acquisition (mentioned the same in last quarter) to expand in the domestic area.

-->The management is working on the patent infringement it got sued in agro space and hopes it will playout in their favor.

-->Major chunk of expense came due to R & D expense and also management admits that their OPEX has increased dur to increase in price of fuel, electricity, coal etc.

-->Management admits that the major chunk of revlimid profits is over by this quarter and again the cycle would start in the end of the last quarter of this year.

-->Management is doing R&D focus on oligopeptides and oncology areas

-->Management is targeting about 8-10 filing this year Management is looking forward to get into general practitioner(GP), Cardio, gynecology and anti-infective

-->Influenza business is no more US subsidiary is not doing well and they are working on this and it will continue for 1-1/2 years.

-->They are currently trialing pheromone? Management feels agro business would contribute 10-15 % of their sales in the coming next 2-3 years

Challenges

Management admits that the generic market has become extremely competitive and expects to grow only by acquiring market share by buying an asset or get into a new product launch.

Terminologies

Exhibit batches: In the pharmaceutical industry, exhibit batches refer to specifically manufactured batches of a drug product that serve a crucial role in the regulatory approval process. They are submitted as part of an application to regulatory agencies to obtain approval for marketing the drug product.

Indian Pharmaceutical Market (IPM): This refers to the entire pharmaceutical industry in India.

Campaign basis: is a planned effort to achieve a specific marketing or sales objective over a defined period. "On a campaign basis" refers to the approach or strategy of implementing these campaigns in a structured way. Campaigns are not random acts. They are meticulously planned with clear goals, target audiences, messaging, budget allocation, and timelines.

Medical Terminologies:

Nexaver: It is a brand name for the medication sorafenib. It is a prescription drug used to treat several types of cancer

Ibruvica: It also known by its generic name ibrutinib, is a prescription medication used to treat several types of cancer.

Oligopeptides: These are short chains of amino acids linked by peptide bonds. They are small molecules compared to proteins, typically consisting of 2 to 20 amino acids. Oligopeptides play an important role in various biological processes, acting as hormones, neurotransmitters, and antibiotics.

PBW: Scientifically known as Pectinophora gossypiella, is a major pest of cotton worldwide, causing significant damage and economic losses.

Pheromones: These are chemical signals that animals, and possibly even humans, use to communicate with each other. They are released by one individual and influence the behavior or physiology of another individual of the same species.